Lilly gains on Jardiance CVOT data

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) reported data from the EMPA-REG OUTCOME cardiovascular outcomes trial (CVOT) of Jardiance empagliflozin plus standard of care (SOC), which the partners had previously said met the study's primary endpoint of time to first CV event and demonstrated superiority vs. placebo plus SOC in CV risk reduction. The data were presented at the European Association for the Study of Diabetes meeting in Stockholm and published in the New England Journal of Medicine. Lilly gained $5.53 to $89.98 on the news.

Jardiance plus SOC significantly reduced the risk of the combined endpoint of CV death, nonfatal myocardial infarction (MI) and nonfatal stroke by 14% vs. placebo plus SOC (HR=0.86; 95.02% CI: 0.74, 0.99; p=0.04 for superiority), and reduced the risk of CV death by 38% (HR=0.62; 95% CI: 0.49, 0.77; p<0.001). There was no significant difference in the risk of nonfatal MI or nonfatal stroke in patients receiving Jardiance vs. placebo. ...